CT-P17_1.4_supplement_final_draft_12July22 (3).docx (463.5 kB)

Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Supplementary methods

dataset

posted on 2023-02-07, 09:34 authored by Yoichiro Ogama, Sangmi Lee, JungBin Cha, Eunjin Choi, DaBee Jeon, Sunghyun Kim, Takanori Tanaka, Miwa Haranaka, YunJu Bae

Pharmacokinetics & safety of CT-P17 (40 mg/0.4 mL) vs reference adalimumab: randomised study in healthy Japanese adults: supplementary methods

History

Usage metrics

Keywords

safety phase I pharmacokinetics monoclonal antibodies Japan immunogenicity CT-P17 biosimilar biologics adalimumab

Licence

CC BY-NC-ND 4.0

Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Supplementary methods

History

Usage metrics

Categories

Keywords

Licence

Exports